ALX-1393

ALX-1393.svg

ALX-1393 is a selective inhibitor of the glycine transporter 1 (GlyT1). GlyT1 is a protein that plays a crucial role in the regulation of glycine levels in the synaptic cleft of neurons. By inhibiting GlyT1, ALX-1393 increases the concentration of glycine in the synaptic cleft, which can enhance NMDA receptor function.

Mechanism of Action

ALX-1393 works by binding to the glycine transporter 1, thereby inhibiting its function. This inhibition prevents the reuptake of glycine from the synaptic cleft back into the presynaptic neuron. As a result, the concentration of glycine in the synaptic cleft increases, which can potentiate the activity of NMDA receptors. NMDA receptors are a type of glutamate receptor that play a key role in synaptic plasticity and memory.

Potential Therapeutic Uses

The modulation of glycine levels through GlyT1 inhibition has been investigated for potential therapeutic applications in various neurological disorders. These include:

• Schizophrenia: Enhanced NMDA receptor function may help alleviate some of the symptoms associated with schizophrenia.
• Cognitive disorders: By improving synaptic plasticity, ALX-1393 could potentially be used to treat cognitive impairments.
• Pain management: GlyT1 inhibitors may have analgesic properties by modulating the glycine levels in the spinal cord.

Research and Development

Research on ALX-1393 is ongoing, with studies focusing on its efficacy and safety in various animal models. Clinical trials are needed to determine its potential therapeutic benefits and any possible side effects in humans.

See also

• Glycine transporter
• NMDA receptor
• Synaptic plasticity
• Schizophrenia
• Cognitive disorders

References

‎